Articles from Mindera Health

Vista, CA, March 18, 2026 (GLOBE NEWSWIRE) -- Mindera Health, a leader in precision medicine for dermatological conditions, and Mountaineer Biosciences today announced the launch of Subtilitas, a precision translational medicine platform designed to bring objective, molecular-level insights into dermatology and immunology clinical research

Using Mind.Px™ test results, altered physician prescribing behavior leads to faster, more effective patient outcomes

Vista, CA, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Mindera Health, a leader in precision medicine for dermatological conditions, today announced their participation in MultiPlan’s national PPO networks. Effective immediately, health plan members who access MultiPlan’s PHCS and MultiPlan Networks have access to Mindera’s Vista, CA-based laboratory that performs its proprietary test Mind.Px™.

Vista, CA, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Mindera Health, a pioneer in precision medicine combining machine learning with Next-Generation Sequencing to create Dermal Intelligence™, announces the addition of John Wegener as the New VP of Sales.

Vista, CA, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Mindera Health, a precision medicine company developing personalized tools to optimize patient outcomes, today announced that additional patent protection has been issued in Japan for the core technology behind the dermal biomarker patch.

Mindera Health and National Psoriasis Foundation partner to improve psoriasis patient outcomes and raise awareness of precision medicine.

Provider status with Medi-Cal will allow Mindera Health to provide its proprietary Mind.Px test to predict biologic class response in plaque psoriasis to the over 15 million Medi-Cal Beneficiaries.

Mindera Health announces the appointment of Kamal Adawi as Chief Financial Officer, effective August 14th, 2024.

San Diego, CA, July 31, 2024 (GLOBE NEWSWIRE) -- Mindera Health Inc. announces the closing of a $14M convertible note financing, led by Mountain Group Partners and other existing investors in anticipation of a Series B financing in 2025. Proceeds will support the continued commercialization of Mindera’s lead product, Mind.Px™.

Innovative collaboration will improve patient outcomes and cost savings through reduced trial-and-error management of biologic therapies

San Diego, CA, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Mindera Health™, a leading provider of precision medicine solutions for psoriasis, today announced that it will be relocating its commercial activities to a new office building at 1221 Liberty Way, Vista, CA 92081 on December 1st, 2023. The new facility is over 19,000 square feet and features a state-of-the-art molecular laboratory. 

San Diego, CA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Mindera Health today announces the signing a commercial agreement with Occum Health, LLC, a healthcare solutions company that is focused on delivering savings and improved benefits to self-insured employers.  Through this agreement, Mindera’s proprietary psoriasis biologic prediction test, Mind.Px, is available to Occum Health’s more than 500 self-insured clients and key strategic partners.

San Diego, CA, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mindera Health™, the developer of Mind.Px, the first realization of precision medicine in psoriasis, announces that it has signed a provider contract with Contigo Health ConfigureNetTM provider network. This commercial agreement will make Mindera's psoriasis biologic prediction test, Mind.Px, available to clients and their health plan members served by clients of Contigo Health.

San Diego, CA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Mindera Health, a precision medicine company developing personalized tools to optimize patient outcomes, today announced that additional patent protection has been issued in Australia for the core technology behind the dermal biomarker patch.

Mindera Corp dba Mindera Health today announced that the General Services Administration (GSA) has awarded a 5-year contract to Mindera Health, enabling access to the Mind.Px™ test for patients with plaque psoriasis considering biologic therapy.

San Diego, CA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Mindera Health™ today announces the signing of a network provider contract with MediNcrease Health Plans, a national provider network and provider advocacy firm. This commercial agreement will make Mindera’s psoriasis biologic prediction test, Mind.Px™, available to the more than 15 million lives served by Clients and Payers of MediNcrease.

Ron Rocca to Become Chief Executive Officer

Project will evaluate Mind.Px’s™ impact on physician “trial and error” prescribing behavior and overall net savings by prescribing the correct biologic class the first time.

Industry Veteran will assist in commercialization of Mind.PxTM to implement precision medicine for biologic treatment of moderate-to-severe psoriasis

By Using Mind.Px, Patients Achieve PASI75 Faster than Treatment-as-Usual Cohort